Objective: In this study, we aimed to determine the effects of chromium picolinate (CrPic) on diabetes, one of the most common and fatal diseases in the world, and its associated oxidative damages.Methods: CrPic (100 μg/kg) and metformin (1000 mg/kg) were orally administered for 21 days in rats with nicotinamide + streptozotocin-induced Type 2 diabetes.Results: Significant decreases in fasting blood glucose levels were observed 14 days after initial administration in both CrPic (p<0.01) and metformin (p<0.001) groups compared with a diabetic control group (DC). Malondialdehyde (MDA) levels of all tissues were significantly higher in the DC group than in a normoglycemic control group (p<0.001). MDA levels of the CrPic group significantly decreased in heart (p<0.05) and liver (p<0.01) tissues. Glutathione (GSH) and catalase (CAT) levels in heart, kidney, and liver tissues increased in CrPic group (GSH p<0.001, p<0.05, and p<0.01; CAT p<0.001, p<0.001, and p<0.05, respectively). Superoxide dismutase enzyme levels significantly increased in CrPic group in the liver tissue (p>0.001), but no such changes were observed in heart and kidney tissues (p>0.05).Conclusion: The results obtained from this study indicate that CrPic may be effective in alleviating hyperglycemia and its consequent oxidative damage in experimental Type 2 diabetes
